ESTRO 2023 | The potential of moderately hypofractionated radiotherapy: analysis & future directions

Sofia Rivera, MD, PhD, Gustave Roussy, Villejuif, France, discusses the potential for further research and analysis based on the two trials conducted on moderately hypofractionated radiotherapy the SKAGEN Trial 1 trial (NCT02384733) and the Phase III HypoG-01 trial (NCT03127995) of locoregional hypo vs normofractionated radiotherapy in early breast cancer. The data collected, including dosimetric and DICOM data, will allow for a comprehensive analysis of the dose-effect relationship, treatment volumes, and techniques used. Dr Rivera mentions the possibility of conducting a prospective meta-analysis of the two trials. Additionally, there are ongoing trials investigating the use of 5 fractions instead of 15 for breast radiotherapy, although the results are expected to take several years to emerge. The shift towards hypofractionated radiotherapy in breast cancer treatment is seen as a significant development and may pave the way for similar approaches in other tumor sites such as the prostate or rectum. This interview took place at the ESTRO congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.